300723 一品红
已收盘 09-04 15:00:00
资讯
新帖
简况
一品红（300723）披露痛风创新药AR882Ⅲ期临床研究达到主要终点，9月3日股价下跌0.81%
证券之星 · 09-03 22:07
一品红（300723）披露痛风创新药AR882Ⅲ期临床研究达到主要终点，9月3日股价下跌0.81%
一品红(300723.SZ)：痛风创新药AR882治疗痛风伴高尿酸血症患者Ⅲ期临床研究达到主要终点
智通财经 · 09-03 17:47
一品红(300723.SZ)：痛风创新药AR882治疗痛风伴高尿酸血症患者Ⅲ期临床研究达到主要终点
一品红(300723.SZ)子公司获得盐酸舍曲林口服溶液注册证书
智通财经 · 09-03 15:54
一品红(300723.SZ)子公司获得盐酸舍曲林口服溶液注册证书
一品红(300723)8月31日股东户数3.11万户，较上期减少5.37%
证券之星 · 09-02 17:31
一品红(300723)8月31日股东户数3.11万户，较上期减少5.37%
一品红H1净利润大幅回升，痛风创新药AR882将迎关键收获期
中金财经 · 08-28
一品红H1净利润大幅回升，痛风创新药AR882将迎关键收获期
股市必读：一品红新发布《第四届董事会第二十二次会议决议公告》
证券之星 · 08-28
股市必读：一品红新发布《第四届董事会第二十二次会议决议公告》
股市必读：一品红中报 - 第二季度单季净利润同比增长15.74%
证券之星 · 08-27
股市必读：一品红中报 - 第二季度单季净利润同比增长15.74%
一品红（300723）披露2026年半年度报告及其摘要，8月26日股价上涨2.74%
证券之星 · 08-26
一品红（300723）披露2026年半年度报告及其摘要，8月26日股价上涨2.74%
图解一品红中报：第二季度单季净利润同比增长15.74%
证券之星 · 08-26
图解一品红中报：第二季度单季净利润同比增长15.74%
一品红(300723.SZ)发布上半年业绩，扭亏为盈至4.85亿元
智通财经 · 08-26
一品红(300723.SZ)发布上半年业绩，扭亏为盈至4.85亿元
一品红(300723)7月31日股东户数3.28万户，较上期减少0.75%
证券之星 · 08-26
一品红(300723)7月31日股东户数3.28万户，较上期减少0.75%
股市必读：一品红新发布《关于全资子公司创新药APH03867片获得临床试验批准通知书的公告》
证券之星 · 08-24
股市必读：一品红新发布《关于全资子公司创新药APH03867片获得临床试验批准通知书的公告》
一品红（300723）披露全资子公司创新药APH03867片获临床试验批准通知书，8月21日股价下跌4.15%
证券之星 · 08-21
一品红（300723）披露全资子公司创新药APH03867片获临床试验批准通知书，8月21日股价下跌4.15%
一品红(300723.SZ)子公司创新药APH03867片临床试验申请获批
智通财经 · 08-21
一品红(300723.SZ)子公司创新药APH03867片临床试验申请获批
一品红最新公告：全资子公司创新药APH04935片获临床试验批准
证券之星 · 08-17
一品红最新公告：全资子公司创新药APH04935片获临床试验批准
股市必读：一品红（300723）8月5日董秘有最新回复
证券之星 · 08-06
股市必读：一品红（300723）8月5日董秘有最新回复
一品红(300723)7月31日股东户数3.28万户，较上期减少0.75%
证券之星 · 08-04
一品红(300723)7月31日股东户数3.28万户，较上期减少0.75%
一品红：2025年11月AR882国内Ⅲ期临床试验完成全部患者入组
证券之星 · 08-04
一品红：2025年11月AR882国内Ⅲ期临床试验完成全部患者入组
一品红：截止至2026年7月31日，公司股东总户数32,828户
证券之星 · 08-04
一品红：截止至2026年7月31日，公司股东总户数32,828户
一品红(300723)7月31日股东户数3.28万户，较上期减少0.75%
证券之星 · 08-03
一品红(300723)7月31日股东户数3.28万户，较上期减少0.75%
加载更多
公司概况
公司名称：
一品红药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2017-11-16
主营业务：
一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是特色儿童药、创新慢病药。
发行价格：
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":35.59,"timestamp":1788505434000,"preClose":36.6,"halted":0,"volume":13511136,"delay":0,"changeRate":-0.0276,"floatShares":419000000,"shares":451999999,"eps":0.4882,"marketStatus":"已收盘","change":-1.01,"latestTime":"09-04 15:00:00","open":37.5,"high":38.8,"low":35.35,"amount":501000000,"amplitude":0.0943,"askPrice":35.59,"askSize":120,"bidPrice":35.58,"bidSize":123,"shortable":0,"etf":0,"ttmEps":0.4882,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":5,"adr":0,"adjPreClose":36.6,"symbolType":"stock","openAndCloseTimeList":[[1788485400000,1788492600000],[1788498000000,1788505200000]],"highLimit":40.26,"lowLimit":32.94,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":8.96,"roa":"--","peRate":72.900451,"roe":"30.08%","epsLYR":-0.7478,"committee":0.057971,"marketValue":16076000000,"turnoverRate":0.0322,"status":1,"floatMarketCap":14919000000},"requestUrl":"/m/hq/s/300723","defaultTab":"news","newsList":[{"id":"2664870661","title":"一品红（300723）披露痛风创新药AR882Ⅲ期临床研究达到主要终点，9月3日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664870661","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664870661?lang=zh_cn&edition=full","pubTime":"2026-09-03 22:07","pubTimestamp":1788444437,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，一品红报收于36.6元，较前一交易日下跌0.81%，最新总市值为165.32亿元。该股当日开盘37.01元，最高37.18元，最低36.36元，成交额达2.34亿元，换手率为1.52%。近日，一品红药业集团股份有限公司全资子公司广州瑞安博开展的AR882胶囊治疗痛风伴高尿酸血症患者Ⅲ期临床试验达到主要终点。AR882在有效性和安全性方面表现良好，未出现因不良事件导致停药或死亡病例。该药为1类创新药，目前尚未实现销售，对公司近期业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300042176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","159992","BK1161","300723","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664731738","title":"一品红(300723.SZ)：痛风创新药AR882治疗痛风伴高尿酸血症患者Ⅲ期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2664731738","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664731738?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:47","pubTimestamp":1788428833,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红 发布公告，公司全资子公司广州瑞安博医药科技有限公司牵头组织开展的AR882胶囊治疗痛风伴高尿酸血症患者Ⅱ/Ⅲ期临床试验，于近日获得顶线分析数据。初步统计结果表明，AR882在痛风伴高尿酸血症参与者中表现出积极的疗效及良好的安全性，试验结果理想，达到预期目的。AR882克服了雷西纳德和苯溴马隆的缺点，能够与尿酸转运蛋白长效结合，延长抑制作用的时间，临床结果显示其药效长达24小时。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","LNGR","BK1161","MEDX","BK1574","IBBQ","BK0239","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664827817","title":"一品红(300723.SZ)子公司获得盐酸舍曲林口服溶液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2664827817","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664827817?lang=zh_cn&edition=full","pubTime":"2026-09-03 15:54","pubTimestamp":1788422055,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于盐酸舍曲林口服溶液的《药品注册证书》。舍曲林用于治疗抑郁症的相关症状，包括伴随焦虑、有或无躁狂史的抑郁症。疗效满意后，继续服用舍曲林可有效地防止抑郁症的复发和再发。舍曲林也用于治疗强迫症。疗效满意后，继续服用舍曲林可有效地防止强迫症初始症状的复发。盐酸舍曲林是一种选择性的5-羟色胺再摄取抑制剂。其作用机制与其对中枢神经元5-羟色胺再摄取的抑制有关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664205890","title":"一品红(300723)8月31日股东户数3.11万户，较上期减少5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664205890","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664205890?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:31","pubTimestamp":1788341460,"startTime":"0","endTime":"0","summary":"证券之星消息，近日一品红披露，截至2026年8月31日公司股东户数为3.11万户，较7月31日减少1763.0户，减幅为5.37%。在化学制药行业个股中，一品红股东户数低于行业平均水平，截至8月31日，化学制药行业平均股东户数为3.66万户。从股价来看，2026年7月31日至2026年8月31日，一品红区间涨幅为2.29%，在此期间股东户数减少1763.0户，减幅为5.37%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200031171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662105181","title":"一品红H1净利润大幅回升，痛风创新药AR882将迎关键收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662105181","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662105181?lang=zh_cn&edition=full","pubTime":"2026-08-28 14:02","pubTimestamp":1787896928,"startTime":"0","endTime":"0","summary":"在全球医药产业加速创新转型的大势下，叠加我国“十五五”规划对生物医药战略性新兴产业的全面赋能，兼具自主知识产权与临床差异化价值的创新药，正成为驱动行业高质量发展的核心引擎。 一品红正是这样一家聚焦儿童药与创新慢病药的创新型生物医药企业，同时公司更坚定推进创新药优先战略。据公开披露，报告期内公司实现营业收入4.92亿元，归母净利润达4.85亿元，同比大幅增长759.11%，成功扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260828/32351573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159992","LNGR","06978","IBBQ","MEDX","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662823600","title":"股市必读：一品红新发布《第四届董事会第二十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662823600","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662823600?lang=zh_cn&edition=full","pubTime":"2026-08-28 01:10","pubTimestamp":1787850619,"startTime":"0","endTime":"0","summary":"公司公告汇总第四届董事会第二十二次会议决议公告一品红药业集团股份有限公司于2026年8月25日召开第四届董事会第二十二次会议，审议通过《关于〈2026年半年度报告及其摘要〉的议案》。该议案经董事会审计委员会审议通过，表决结果为同意5票，反对0票，弃权0票。该表已经公司第四届董事会第二十二次会议批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800003289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662463767","title":"股市必读：一品红中报 - 第二季度单季净利润同比增长15.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662463767","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662463767?lang=zh_cn&edition=full","pubTime":"2026-08-27 00:57","pubTimestamp":1787763431,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年中报显示归母净利润4.85亿元，同比上升759.11%；扣非净利润为-1.31亿元，同比下降21.26%。业绩披露要点财务报告2026年中报显示，上半年度主营收入4.92亿元，同比下降15.77%；归母净利润4.85亿元，同比上升759.11%；扣非净利润-1.31亿元，同比下降21.26%；2026年第二季度单季度主营收入1.06亿元，同比下降48.63%；单季度归母净利润-1.1亿元，同比上升15.74%；单季度扣非净利润-1.29亿元，同比下降4.15%；负债率58.11%，投资收益5.74亿元，财务费用2879.63万元，毛利率57.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700002803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662177607","title":"一品红（300723）披露2026年半年度报告及其摘要，8月26日股价上涨2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662177607","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662177607?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:04","pubTimestamp":1787753091,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，一品红报收于35.97元，较前一交易日上涨2.74%，最新总市值为162.47亿元。该股当日开盘35.07元，最高36.0元，最低34.87元，成交额达2.69亿元，换手率为1.81%。近日，一品红药业集团股份有限公司召开第四届董事会第二十二次会议，审议通过了《关于<2026年半年度报告及其摘要>的议案》。2026年半年度报告内容真实、准确、完整，无虚假记载、误导性陈述或重大遗漏，已披露于巨潮资讯网。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600051744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662879788","title":"图解一品红中报：第二季度单季净利润同比增长15.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662879788","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662879788?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:03","pubTimestamp":1787738583,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红2026年中报显示，上半年度公司主营收入4.92亿元，同比下降15.77%；归母净利润4.85亿元，同比上升759.11%；扣非净利润-1.31亿元，同比下降21.26%；其中2026年第二季度，公司单季度主营收入1.06亿元，同比下降48.63%；单季度归母净利润-1.1亿元，同比上升15.74%；单季度扣非净利润-1.29亿元，同比下降4.15%；负债率58.11%，投资收益5.74亿元，财务费用2879.63万元，毛利率57.44%。财报数据概要请见下图:本文数据来源于一品红2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600041221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792596","title":"一品红(300723.SZ)发布上半年业绩，扭亏为盈至4.85亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792596","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662792596?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:49","pubTimestamp":1787737754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布2026年半年度报告，报告期内，公司实现营业收入4.92亿元，同比下降15.77%。实现归属于上市公司股东的净利润4.85亿元。归属于上市公司股东的扣除非经常性损益净亏损1.31亿元。截至2026年6月30日，公司总资产44.88亿元。2026年是公司创新转型的加速之年，行业竞争愈发激烈，公司经营也面临诸多挑战。公司与全体员工依始终坚持科技创新锐意进取，创新转化成果可期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"一品红(300723.SZ)发布上半年业绩，扭亏为盈至4.85亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792378","title":"一品红(300723)7月31日股东户数3.28万户，较上期减少0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792378","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662792378?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:48","pubTimestamp":1787737684,"startTime":"0","endTime":"0","summary":"证券之星消息，近日一品红披露，截至2026年7月31日公司股东户数为3.28万户，较6月30日减少248.0户，减幅为0.75%。在化学制药行业个股中，一品红股东户数低于行业平均水平，截至7月31日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年6月30日至2026年7月31日，一品红区间跌幅为5.31%，在此期间股东户数减少248.0户，减幅为0.75%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600040288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661437902","title":"股市必读：一品红新发布《关于全资子公司创新药APH03867片获得临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661437902","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661437902?lang=zh_cn&edition=full","pubTime":"2026-08-24 01:13","pubTimestamp":1787505191,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，一品红报收于36.75元，下跌4.15%，换手率3.8%，成交量15.91万手，成交额5.82亿元。公司公告汇总：全资子公司创新药APH03867片获国家药监局临床试验批准，适应症为痛风伴高尿酸血症。APH03867片为化学药品1类创新药，属于新型口服、非肽类小分子URAT1抑制剂，通过抑制肾脏尿酸重吸收，促进尿酸排泄，降低血尿酸水平。该药品在境内外均未上市，目前临床试验申请已获批准，后续需按要求开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400000820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","300723","BK1161","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661696002","title":"一品红（300723）披露全资子公司创新药APH03867片获临床试验批准通知书，8月21日股价下跌4.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661696002","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661696002?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:36","pubTimestamp":1787305013,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，一品红报收于36.75元，较前一交易日下跌4.15%，最新总市值为166亿元。一品红药业集团股份有限公司于近日披露公告，其全资子公司广州一品红制药有限公司自主研发的创新药APH03867片获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展针对痛风伴高尿酸血症适应症的临床试验。APH03867片为化学药品1类创新药，属于新型口服、非肽类小分子URAT1抑制剂，通过抑制肾脏尿酸重吸收，促进尿酸排泄，降低血尿酸水平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100032022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","159992","BK1161","300723","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661251135","title":"一品红(300723.SZ)子公司创新药APH03867片临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2661251135","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661251135?lang=zh_cn&edition=full","pubTime":"2026-08-21 11:48","pubTimestamp":1787284128,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03867片的药物临床试验申请已获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，将于近期开展临床试验。据悉，APH03867片是由公司自主研发的一种新型口服、非肽类小分子URAT1抑制剂(全称：Urate Transporter 1，中文译为：尿酸转运蛋白1)抑制剂，通过抑制肾脏中URAT1的活性，阻断尿酸在肾小管的重吸收，增加尿酸排泄，达到有效降低血尿酸的效果，可用于改善高尿酸血症和痛风症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","MDTX","BK0239","IBBJ","06978","PSYK","BK1574","LNGR","IBBQ","159992","BMED","BK1161","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660548945","title":"一品红最新公告：全资子公司创新药APH04935片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660548945","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660548945?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:01","pubTimestamp":1786960905,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司全资子公司广州一品红制药自主研发的创新药物APH04935片获国家药监局批准开展临床试验，拟用于控制体重及长期减重管理。该药为高选择性小分子GLP-1R激动剂，属化学药品1类创新药，境内外均未上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700024788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","300723","BK1161","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652137","title":"股市必读：一品红（300723）8月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657652137?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:19","pubTimestamp":1785950349,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，一品红报收于36.22元，上涨1.66%，换手率2.33%，成交量9.76万手，成交额3.51亿元。董秘最新回复投资者： 为何疼风药国内三期依然还在试验，那么久了，可否出来解释一下董秘： 尊敬的投资者您好，感谢您对公司的关注。2025年11月，公司在研的痛风创新药AR882国内Ⅲ期临床试验完成全部患者入组。目前，正在进行关键性Ⅲ期临床试验，试验进展顺利。当日关注点交易信息汇总：8月5日主力资金净流入902.15万元，占总成交额2.57%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656531213","title":"一品红(300723)7月31日股东户数3.28万户，较上期减少0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656531213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656531213?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:52","pubTimestamp":1785837142,"startTime":"0","endTime":"0","summary":"证券之星消息，近日一品红披露，截至2026年7月31日公司股东户数为3.28万户，较6月30日减少248.0户，减幅为0.75%。在化学制药行业个股中，一品红股东户数低于行业平均水平，截至7月31日，化学制药行业平均股东户数为3.6万户。从股价来看，2026年6月30日至2026年7月31日，一品红区间跌幅为5.31%，在此期间股东户数减少248.0户，减幅为0.75%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400030080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656535231","title":"一品红：2025年11月AR882国内Ⅲ期临床试验完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2656535231","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656535231?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:21","pubTimestamp":1785831674,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：AR882三期临床已经到八月份了，去年十一月最后一组入组，到5月份应该已经结束了，请问进度如何，预计八月份能揭盲吗？一品红回复：尊敬的投资者您好，感谢您对公司的关注。2025年11月，公司在研的痛风创新药AR882（氘泊替诺雷）国内Ⅲ期临床试验完成全部患者入组。目前，正在进行关键性Ⅲ期临床试验，试验进展顺利。此外，药品研发具有周期长、投入高、风险大等特点，敬请广大投资者谨慎决策，注意投资风险。祝您投资愉快！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400026659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656535298","title":"一品红：截止至2026年7月31日，公司股东总户数32,828户","url":"https://stock-news.laohu8.com/highlight/detail?id=2656535298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656535298?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:21","pubTimestamp":1785831672,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至7月底公司股东人数是多少，谢谢！一品红回复：尊敬的投资者您好，感谢您对公司的关注。截止至2026年7月31日，公司股东总户数32,828户。祝您投资愉快。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400026654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656327573","title":"一品红(300723)7月31日股东户数3.28万户，较上期减少0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656327573","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656327573?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:43","pubTimestamp":1785750230,"startTime":"0","endTime":"0","summary":"证券之星消息，近日一品红披露，截至2026年7月31日公司股东户数为3.28万户，较6月30日减少248.0户，减幅为0.75%。在化学制药行业个股中，一品红股东户数低于行业平均水平，截至7月31日，化学制药行业平均股东户数为3.6万户。从股价来看，2026年6月30日至2026年7月31日，一品红区间跌幅为5.31%，在此期间股东户数减少248.0户，减幅为0.75%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300024042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788573209718,"stockEarnings":[{"period":"1week","weight":-0.0412},{"period":"1month","weight":-0.0174},{"period":"3month","weight":-0.053},{"period":"6month","weight":0.115},{"period":"1year","weight":-0.4709},{"period":"ytd","weight":0.0608}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0133},{"period":"3month","weight":-0.0242},{"period":"6month","weight":-0.0471},{"period":"1year","weight":0.0436},{"period":"ytd","weight":-0.0098}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31065人(较上一季度减少5.37%)","perCapita":"13494股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":" 一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是特色儿童药、创新慢病药。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}